
PARI Product Overview




PARI Product Overview

Valid from June 2025

www.pari.com

Conditions of Sale

This Product Overview applies to countries marked blue on the map.
The Product Overview can be used as reference for all other countries worldwide.



General Terms and Conditions of PARI GmbH can be found on page 27.
Prices listed are recommended retail prices.
Prices are subject to change.
Items offered in packages cannot be supplied singly, unless otherwise specified.
IFU = languages included in Instructions for Use
f/m = female/male
f/f = female/female
Minimum order amount 200.00 €
Minimum order charge 10.00 €
Misprint excepted
Dataprivacy policy available = https://www.pari.com/int/data-protection/

The availability of the products listed in this document and / or the contents may vary by country. Please contact your local sales representative for more details.

GLOSSARY

RDDR ..... ***Respirable Drug Delivery Rate in µl/min (droplets < 5 µm)***

MMAD ..... ***Mass Median Aerodynamic Diameter in µm,*** *50 % of the aerosol mass is distributed in droplets that are smaller than or equal to the MMAD, and 50 % in droplets that are larger.*

Mass fraction < 5 µm ..... ***Respirable Fraction (RF) in percentage****, proportion of respirable droplets < 5 µm available for the treatment of the lower airways.*

Content

PARI BOY® Classic 4
PARI BOY® Junior 4
PARI BOY® Pro 5
PARI COMPACT*2* 5
VELOX® 6
eFlow®*rapid* nebuliser system 7
PARI SINUS*2* 8
PARI Montesol Nasal douche 9
Which Year Pack matches which PARI inhalation device? 10
Nebulisers 11
PARI LC SPRINT® family 12
PARI PIF control 13
Masks 14
Spare parts and accessories 15
VORTEX® 16
PARI NaCl 0.9 % Inhalation Solution Isotonic (NaCl 0.9 %) 18
MucoClear® 3 % Inhalation Solution Hypertonic (NaCl 3 %) 19
MucoClear® 6 % Inhalation Solution Hypertonic (NaCl 6 %) 19
PARI O-PEP® 20
PARI PEP S System 20
PARI Filter Valve Set 21
Hospital packs and accessories 22
PARI – scientifically tested and used worldwide 23

GENERAL TERMS AND CONDITIONS OF PARI GMBH 27

PARI BOY® Classic

The classic device in acute and chronic respiratory diseases

Aerosol characteristics:	
Blue nozzle insert:	
RDDR:	99 µl/min
MMAD:	3.8 µm
Mass fraction < 5 µm:	62 %
Measurement according to EN ISO 27427:2020-2 (with salbutamol)	



The PARI BOY Classic is ideal choice for the therapy of acute or chronic respiratory diseases in children, adolescents and adults. It can be used to treat diseases such as bronchial asthma, allergic asthma and acute or chronic bronchitis.

- For all patients aged 4 years and up who want a quick and simple nebuliser treatment
- Large quantity of active substance in the lungs in a short time thanks to the high-performance compressor and PARI LC SPRINT nebuliser
- With PIF control – the integrated "training tool" that helps patients to learn effective inhalation technique

PARI BOY® Junior

Specially developed for the treatment of babies and toddlers

Aerosol characteristics:	
Yellow nozzle insert:	
RDDR:	117 µl/min
MMAD:	3.1 µm
Mass fraction < 5 µm:	73 %
Red nozzle insert:	
RDDR:	80 µl/min
MMAD:	2.8 µm
Mass fraction < 5 µm:	80 %
Measurement according to EN ISO 27427:2020-2 (with salbutamol)	



The PARI BOY Junior is a good choice for the inhalation therapy of babies and toddlers. It offers the option to produce fine or even extra fine droplets and the equipment is specially tailored to the needs of small patients. It is therefore ideal for highly efficient treatment even for babies as young as a month old.

- Equipment for babies from the first month of life: PARI BABY mask with BABY bend
- Large quantity of active substance in the lungs in a short time thanks to the high-performance compressor and PARI LC SPRINT nebuliser
- Variable droplet spectrum – fine droplets (yellow nozzle insert) for infants or extra fine droplets (red nozzle insert) specifically for babies or infants in obstructive phases

PARI BOY® Pro

Flexible, with variable droplet spectrum and optional intermittent nebulising



Aerosol characteristics:	
Blue nozzle insert:	
RDDR:	99 µl/min
MMAD:	3.8 µm
Mass fraction < 5 µm:	62 %
Red nozzle insert:	
RDDR:	80 µl/min
MMAD:	2.8 µm
Mass fraction < 5 µm:	80 %
Measurement according to EN ISO 27427:2020-2 (with salbutamol)	

The PARI BOY Pro is the right device for the therapy of severe and chronic respiratory diseases of the lower airways. An extensive range of extra equipment makes the PARI BOY Pro the versatile device for airway treatment.

- PARI LC SPRINT nebuliser with extra nozzle insert (red) for extra-fine droplets
- Optional intermittent nebulising for combined physiotherapy
- With PIF control – the integrated "training tool" that helps patients to learn effective inhalation technique

PARI COMPACT2

Proven effective in the treatment of diseases of the lower airways



Aerosol characteristics:	
PARI LC PLUS nebuliser:	
RDDR:	64 µl/min
MMAD:	4.5 µm
Mass fraction < 5 µm:	53 %
PARI LC PARI LC SPRINT COMPACT nebuliser (orange nozzle insert):	
RDDR:	105 µl/min
MMAD:	3.4 µm
Mass fraction < 5 µm:	69 %
Measurement according to EN ISO 27427:2020-2 (with salbutamol)	

The PARI COMPACT2 inhalation system is the cost-effective alternative from PARI delivering reliability and PARI quality at an affordable price.

- With PARI LC PLUS nebuliser or PARI LC SPRINT COMPACT nebuliser*
- High efficiency (RDDR) – high lung deposition in a short inhalation time
- Easy to operate
- Safe hygiene without the use of chemicals

* dependent on country

VELOX®

Mobile and quiet for on the go

Aerosol characteristics*:	
TOR:	497 mg/min
MMD:	3.8 µm
Mass fraction < 5 µm:	74 %
Measurement using laser diffraction (Helos SympaTec) at 23 °C and 50 % relative humidity. Nebulised medium: 0.9 % NaCl (4 ml). Inspiratory flow: 20 l/min.	



The VELOX is our portable inhalation device with innovative vibrating membrane technology. It is suitable for people with respiratory diseases and for everyone who wants to soothe their respiratory tracts and prevent colds – when exercising, after days that take their toll on the vocal chords or while on holiday. Thanks to its almost silent operation, the VELOX is ideal for inhalation treatment in babies and infants.

- Quick and efficient inhalation treatment through high aerosol output with a high proportion of respirable droplets
- Maximum mobility thanks to mains or battery operation
- Almost silent to use
- Constant short treatment times due to VELOXcare keeping the membrane unclogged

** Measurements according to EN ISO 27427:2020-2 are under preparation*

eFlow®*rapid* nebuliser system

With a newly designed eBase® controller for better handling and more mobility



The next generation

Aerosol characteristics:	
RDDR:	275 µl/min
Mass percentage < 5 µm:	55 %
Measurement according to EN ISO 27427:2020-2 (with salbutamol)	

The eFlow®*rapid* nebuliser system with the new eBase® Controller is suitable for treating a wide range of diseases of the lower airways. It stands for efficient, safe and fast inhalation therapy combined with even more benefits:

- Flexible use thanks to a handy controller design, battery pack, and a compact, lightweight, and quiet device
- Customisable controller lights and sounds to suit individual preferences
- Time-saving with immediate shut-off at the end of the inhalation therapy and short nebulisation times [1] – thanks to eFlow® technology

The eBase® Controller is compatible with nebulisers based on the eFlow® Technology, including the eFlow®*rapid*, Tolero®, Altera®, and Zirela®.

The eBase® Controller is compatible with:



eFlow®*rapid*

the eFlow®*rapid* nebuliser – for use with approved inhalation solutions such as:

- Colistimethate sodium
- Tobramycin
- Dornase alfa
- Isotonic and hypertonic saline solutions

Tolero® for Vantobra®

and additional medication-specific nebulisers including:

- Altera® for Cayston®
- Zirela® for Quinsair®

Please take note of the instructions for use for the medication in question.

[1] Naehrig S et al. Eur J Med Res 2011; 16(2): 63-66.

PARI SINUS2

Pulsating aerosol for the treatment of sinusitis

Aerosol characteristics:	
MMAD:	3.0 µm
Mass fraction < 5 µm:	66.6 %

Aerosol characteristics of the PARI LC SPRINT SINUS nebuliser were measured with the PARI SINUS2 compressor. Particle size was measured using the Next Generation Impactor (NGI). Measurement at 23 °C and 50 % relative humidity. Nebulised medium 2 ml salbutamol (1 mg/1 ml) jet flow 4.6 l/min.



The PARI SINUS*2* has been specially designed for the treatment of rhinosinusitis. In addition to the known advantages of aerosol therapy, the PARI SINUS*2* creates a pulsating aerosol. This reaches the paranasal sinuses via the ostia more easily than traditional aerosols. Medications and saline solutions can get to work exactly where they are needed.

- Stubborn mucous and secretions are loosened
- Saline solutions, antibiotics and steroids were used in studies with the PARI SINUS*
- Suitable for persons aged 6 years and over
- The lungs can also be treated with a PARI nebuliser for the lower airways, e.g. PARI LC SPRINT

** PARI SINUS and PARI SINUS2 have the same technical characteristics and aerosol performance.*

PARI Montesol Nasal douche

Natural, effective and gentle cleaning of the nose



The Nasal douche is a generally very well tolerated and extremely effective method of soothing and moisturising the nasal mucuos, which has been a tried-and-tested method in the yoga tradition for over a thousand years. Compact and easy to handle – the PARI Montesol Nasal douche is a natural remedy to prevent and treat sniffles, colds and allergies.

- Compact and easy to handle design
- Easy to use
- Safe and hygienic cleaning, can be boiled
- Suitable from 4 years

Which Year Pack matches which PARI inhalation device?



		PARI SINUS2	PARI BOY® Classic	PARI BOY® Junior	PARI BOY® Pro	PARI COMPACT2
Upper airways						
PARI SINUS2 Year Pack 	• PARI LC SPRINT SINUS nebuliser • PARI SINUS tube system • Filter • Nasal plug	✔	–	–	–	–
Lower airways						
PARI BOY® Classic Year Pack 	• PARI LC SPRINT nebuliser with/without** PIF control (blue nozzle insert) • Universal mouthpiece • 2 Filters* • Connection tube (f/m)	✔	✔	✔	✔	✔
PARI BOY® Junior Year Pack 	• PARI LC SPRINT Junior nebuliser with PIF control (yellow nozzle insert) • Additional red nozzle insert • Universal mouthpiece • 2 Filters* • Connection tube long (f/m)	✔	✔	✔	✔	✔
PARI BOY® Pro Year Pack 	• PARI LC SPRINT nebuliser with PIF control (blue nozzle insert) • Additional red nozzle insert • Universal mouthpiece • 2 Filters* • Connection tube (f/m)	✔	✔	✔	✔	✔
PARI COMPACT2 Year Pack – WE 	• PARI LC PLUS nebuliser • Universal mouthpiece • Filter • Connection tube (f/m)	✔	✔	✔	✔	✔
PARI COMPACT2 Year Pack – Nordics, & UK 	• PARI LC SPRINT COMPACT nebuliser (orange nozzle insert) • Universal mouthpiece • Filter • Connection tube (f/m)	✔	✔	✔	✔	✔
If used regularly the nebuliser, connection tube and filter have to be replaced each year. PARI Year Packs ensure:		» Lasting effective inhalation treatment and reliable hygiene » The right nebuliser to meet your needs is readily available » Hygienic inhalation treatment for the rest of the family: parents or siblings should use their own nebulisers				

*1 filter each for the PARI BOY compressor Type 085 and Type 130
** dependent on country

Nebulisers

Upper airways

from birth

PARI LC SPRINT® XLent nebuliser
With transparent nozzle insert



from 6 years

PARI LC SPRINT® SINUS nebuliser
Availabe as
PARI SINUS*2* Year Pack (for PARI SINUS*2* Compressor, Type 128)
PARI LC SPRINT SINUS Year Pack (for PARI SINUS Compressor, Type 028)



Lower airways

from birth

PARI LC SPRINT® BABY nebuliser
With red nozzle insert



With size 0 mask	With size 1 mask	With size 2 mask	With size 3 mask
for premature babies	for age 0 – 1	for age 1 – 3	for approx. 3 years and older

PARI LC SPRINT® Junior nebuliser
With yellow nozzle insert



Children and adults

PARI LC SPRINT® nebuliser
With blue nozzle insert



PARI LC SPRINT® Tracheo with Adapter
With orange nozzle insert



PARI LC SPRINT® Tracheo with Mask
With orange nozzle insert



PARI LC SPRINT® STAR nebuliser
With red nozzle insert



PARI LC PLUS®



PARI LC SPRINT® family

Nebulisers with variable droplet sizes



The nebulisers in the PARI LC SPRINT family come with different nozzle inserts that create various droplet sizes thus offering solutions tailored to the user's individual requirements in terms of indication and age group. The PARI LC SPRINT nebuliser consists of only a few individual parts and is therefore quick and easy to put together and take apart. It is also quick and easy to clean. Its user-friendliness makes inhalation treatment as pleasant as possible, while at the same time being efficient.

- Various droplet sizes produced by different nozzle inserts
- Aerosol gets exactly where it needs to in the airways
- Flexible use depending on age and indication

Upper airways

Lower airways



Blue
nozzle insert

Droplets for the central area of the lungs in older children and adults

Yellow
nozzle insert

Small droplets for small airways in babies and children

Red
nozzle insert

The finest droplets for the small airways of babies and premature babies and for the peripheral or disease-related obstructive lung areas of adults and children

Orange
nozzle insert

Fine droplets for the lower airways of all age groups.


In combination with the pulsation of the PARI SINUS*2* for efficient deposition in the paranasal sinuses

Transparent
nozzle insert

Extra large droplets for the upper airways

PARI PIF-Control

Training for effective inhalation




The PARI LC SPRINT nebuliser is fitted with the PIF-Control System (PIF = Peak Inspiratory Flow). PIF helps to control the inhalation of your medication. With a steady, relaxed breath in, more medication is delivered to the right place in the lungs. If you breathe in too quickly, you will notice a gentle resistance – this is a sign for you to relax your breathing a little and not to breathe in so sharply. If you don't feel any resistance, you are inhaling correctly and can be confident in knowing that your medication is getting to your lower airways.

Integrated into the PARI LC SPRINT nebulisers that are included in devices in the PARI BOY family*:


- PARI BOY Junior
- PARI BOY Pro
- PARI BOY Classic

And in all PARI LC SPRINT nebulisers for the lower airways (exception: PARI LC SPRINT Tracheo, PARI LC SPRINT CENTRAL, PARI LC SPRINT SP).

Quick inspiration



Slow inspiration



Modified after Laube et al. J. Allergy Clin Immunol 89(2):510 – 518, 1992

** dependent on country*

Masks



PARI BABY mask “size 0” with BABY bend
For premature babies from 2.5 kg



PARI BABY mask “size 1” with BABY bend
For babies aged from 0 to 1 year



PARI BABY mask “size 2” with BABY bend
For babies and infants aged from 1 to 3 years



PARI BABY mask “size 3” with BABY bend
For children approx. 3 years and older



PARI adult mask soft
With elastic strap
For adults
Sterilisable with mask stabiliser



PARI child mask soft “Spiggy”
With elastic strap
For children aged 4 years and older
Sterilisable with mask stabiliser



PARI baby mask soft
For babies aged 6 months to approx. 3 years



PARI SMARTMASK® Baby
For children aged 2 years and younger
Very soft and comfortable



PARI SMARTMASK® Kids
For children aged 2 years and older
Very soft and comfortable



PARI SMARTMASK®
For adults
Very soft and comfortable

Spare parts and accessories



Mouthpiece without valve
Replacement part for PARI PEP S system, PARI Filter Valve Set without expiratory valve



Universal mouthpiece
Replacement part for PARI nebulisers



LC Interrupter
For optional interval nebulisation
For all PARI jet nebulisers



PARI LC SPRINT SINUS Application-Set
With bend (45 degrees), vibration connection, nasal joining piece and nasal plug
Can only be used with PARI LC SPRINT SINUS nebuliser



PARI Tracheo Mask
Spare part for PARI LC SPRINT Tracheo with Mask
With PARI Tracheo mask adapter and PARI tracheostomy mask



Connection tubing (1,20 m, f/m)
Suitable for use with all PARI compressors except PARI COMPACT (Typ 052)



Connection tubing long (1,9 m, f/m)
Suitable for use with all PARI compressors except PARI COMPACT (Typ 052)



Connection tubing (1,20 m, f/f)
Suitable for use with PARI COMPACT (Typ 052) and PARI CENTRAL
When used with a tubing adapter, also suitable for all other PARI compressors



Connection tubing (1,9 m, f/f)
Suitable for use with PARI COMPACT (Typ 052) and PARI CENTRAL
When used with a tubing adapter, also suitable for all other PARI compressors



PARI SINUS Tubing System (2x 1,2 m, f/m)
Suitable for use with PARI SINUS*2* (Typ 128) / PARI SINUS (Typ 028) only



Tubing Adaptor f/f to f/m
Available singly and in packs of 50



PARI BAG
Carrying bag for use with all PARI compressors

VORTEX®

The antistatic holding chamber – Attach. Breathe. Relax.


The VORTEX® is suitable for every age

Thanks to the exchangeable mouthpiece and the removable baby, child and adult masks, the VORTEX is perfectly suitable for all age groups.



The VORTEX® antistatic holding chamber facilitates comfortable, safe and efficient inhalation therapy with metered-dose inhalers

- **Extra soft baby and child masks:** The newly developed baby and child masks support extra comfortable inhalation therapy for stress-free use. The soft mask rim adapts easily to facial contours, ensuring a secure seal with minimal application pressure
- The **antistatic metal chamber** ensures **excellent aerosol performance** and reliable dosing. The antistatic properties prevent the fine drug particles adhering to the walls. This ensures the uniform and effective administration of the medication
- **Easy & flexible use:** The patented one-handed operation aid means you can hold the VORTEX and trigger the metered-dose inhaler using just one hand
- **Safe hygiene:** Thanks to its stable metal chamber and removable masks, the VORTEX, including the baby and child mask, can be boiled, sterilised, autoclaved and washed in the dishwasher
- Suitable for most standard metered-dose inhalers



With the VORTEX holding chamber, the medication reaches the lungs reliably.

VORTEX®

Product variants



VORTEX with baby mask

0–1½ years
With one-handed operation aid

0–1½



VORTEX with child mask

1–4 years

1–4



VORTEX with mouthpiece

From 4 years



VORTEX with adult mask soft

With one-handed operation aid



VORTEX Tracheo

Antistatic inhalation aid for tracheostomised patients
Designed for use with standard 15 mm tracheostomy connectors

Useful accessories



VORTEX baby mask

0–1½ years



VORTEX child mask

1–4 years



VORTEX adult mask soft

With mask connector




VORTEX mouthpieces

Pack of 10

PARI NaCl 0.9 % Inhalation Solution Isotonic (NaCl 0.9 %)

Humidification solution




The PARI NaCl 0.9 % Inhalation Solution has a broad spectrum of potential areas of use: To moisten and soothe the airways, as a supportive measure for colds or as a carrier solution for medications.

The PARI NaCl 0.9 % solution for inhalation supports the airways' natural self-cleaning mechanism. Inhalation with isotonic saline solution is also suitable as prophylaxis for respiratory diseases.

- Moistens the airways
- Suitable for infants, children and adults, also for pregnant women and breastfeeding mothers
- Sterile and preservative-free

MucoClear® 3 % Inhalation Solution Hypertonic (NaCl 3 %)

For mobilising secretions




MucoClear 3 % Inhalation Solution dissolves mucous in respiratory diseases with secretion formation.

MucoClear 3 % supports the airways' self-cleaning mechanism and facilitates expectoration. It is also recommended for patients who would not tolerate inhalation of more concentrated saline solutions, such as MucoClear 6 %, but would nevertheless benefit from a mucous-dissolving effect.

- Dissolves mucous
- Proven by studies to be effective and safe
- For infants, children and adults
- Sterile and preservative-free

MucoClear® 6 % Inhalation Solution Hypertonic (NaCl 6 %)

For mobilising secretions



MucoClear 6 % Inhalation Solution dissolves mucous and facilitates expectoration.

The hypertonic saline solution is recommended for cystic fibrosis, Chronic Obstructive Pulmonary disease and bronchiectasis, for example.
The higher salt concentration means that the mucous-dissolving effect of MucoClear 6 % is stronger.

- Dissolves mucous
- Proven by studies to be effective and safe
- For infants, children and adults
- Sterile and preservative-free

PARI O-PEP®

Efficiently dissolves bronchial mucous and strengthens the airways



The PARI O-PEP (oscillating PEP) is the respiratory therapy device for effective mucous removal, which is comfortable to use thanks to its oval mouthpiece.

- Reduces unproductive cough and shortness of breath
- Including a small bag for hygienic storage and transport
- Dishwasher-safe and sterilisable at up to 134°C

PARI PEP S System

Time-saving combination of physiotherapy and inhalation treatment



With the PARI PEP S system, patients can use physiotherapeutic methods in addition to drug treatments to alleviate their symptoms, such as cough, shortness of breath, and the formation of secretions.

- Mobilises secretions and facilitates expectoration
- Stabilises the airways through individually adjustable expiratory resistance: Counteracts bronchial collapse
- Manometer to adjust expiratory resistance and for control during PEP therapy (available as accessories)
- Can even be used in physiotherapy without a nebuliser

PARI Filter Valve Set

Filters the expired air and excess aerosol



Filter pads

are available in a pack of 30,
pack of 100 and pack of 1000

The PARI Filter Valve Set protects those indirectly involved in the inhalation, e.g. relatives and nurses, from the medication aerosol. The integrated valve system guarantees efficient inhalation therapy.

- Improved safety in nebuliser therapy in hospitals
- Can be combined with the nebulisers PARI LC SPRINT, PARI LC SPRINT CENTRAL, PARI LC SPRINT SP, PARI LC SPRINT XLent, PARI LC PLUS, PARI vibrating membrane nebulisers (eFlow rapid, VELOX) and the PARI PEP S system

Hospital packs and accessories



VORTEX® hospital pack (10 units)

Antistatic holding chamber with mouthpiece
All components can be sterilized and are suitable for use with multiple patients



PARI LC SPRINT® hospital pack (10 units)

Nebuliser with valve system and PIF control (blue nozzle insert) and mouthpiece (without connection tube)



PARI LC SPRINT® Junior hospital pack (5 units)

Nebuliser with valve system and PIF control for children (yellow nozzle insert) and mouthpiece (without connection tube)



PARI LC SPRINT® STAR hospital pack (5 units)

Nebuliser with valve system and PIF control (red nozzle insert) and mouthpiece (without connection tube)



PARI LC SPRINT® CENTRAL

Nebuliser specifically for use with PARI CENTRAL in the hospital



Mask stabiliser (for PARI adult mask soft) (5 units)

Stabiliser for sterilisation in autoclaves. Only fits PARI adult mask soft



Mask stabiliser (for PARI child mask soft) (5 units)

Stabiliser for sterilisation in autoclaves. Only fits PARI child mask soft



PARI CENTRAL AIR

Wall outlet for connection with the central gas supply system in hospitals



PARI CENTRAL Clip (5 units)

Practical mount for PARI LC SPRINT or PARI LC PLUS Nebuliser, PARI LC SRRINT CENTRAL and connection tubing at PARI CENTRAL

PARI – scientifically tested and used worldwide

The stated goal of research and development at PARI and PARI Pharma is to provide optimised comprehensive solutions, i.e. to develop medications and inhalation systems for defined pathologies and patient groups. The focus of our development work is always the needs of patients and making inhalation treatment as simple, comfortable and efficient as possible for them. The advantages for patients include short inhalation times combined with the economical use of medications or easier and more comfortable use by reducing frequency of use. This constant striving for efficient systems has been documented in numerous scientific publications:

PARI LC PLUS nebuliser

Adeboyeku D, Scott S, Hodson ME. Journal of Cystic Fibrosis 2006.
Agoramurthi K, Berlinski A. Pharmaceutics. 2023;16(1).
Balcke A, Jahn D, Bucholski A, et al. ISAM Congress. 2001.
Basu K, et al. Ann Allergy Asthma Immunol. 2009;103(5):436-41.
Bauer A et al. Respiratory Care, October 2009, Vol 54, No 10.
Berg EB, Picard RJ. Respir Care. 2009;54(12):1671-8.
Berlinski A, Hayden JP. NACF conference 2010, Poster 445.
Berlinski A, Waldrep JC, Journal of Aerosol Medicine, Volume 14, Number 2, 2001.
Berlinski A. Respir Care. 2013;58(12):2076-2086.
Berlinski A. Respir Care. 2021 May 4:respcare.08834. doi: 10.4187/respcare.08834.
Bilton D et al. NACF conference 2014, Poster 284w.
Bilton D et al. ECFC Congress 2014.
Birchall JC et al. International Journal of Pharmaceutics 197 (2000) 221-231.
Bitterle E, Müller D, Tiffin N, et al. Pediatr Pulmonol. 2007;(suppl 30):336.
Brendel E, Luithlen A, Bruendl K, et al. Am J Resp Care. 2010;181.
Bucholski A, Hug M, Keller M. ISAM 2007.
Buttini F et al. J Hosp Infect. 2023 Dec 23;145:77-82. doi: 10.1016/j.jhin.2023.12.008.
Byrne NM, Keavey PM, Perry JD, Gould FK, Spencer DA. Arch Dis Child. 2003 Aug;88(8):715-8.
Cegla UH, Jost JH, Harten A, Weber T. Pneumologie. 2001 Oct;55(10):465-9.
Clavel A et al. J Cyst Fibros. 2007 Apr;6(2):137-43. Epub 2006 Jul 12.
Coates AL et al. Pediatr Pulmonol. 2011 Apr;46(4):401-8.
De Boer AH, Hagedoorn P, Frijlink HW. International Journal of Pharmaceutics 268 (2003) 59-69.
Dellon EP, Donaldson SH, Johnson R, Davis SD. Pediatr Pulmonol. 2008;43(11):1100-1106.
Dennis JH, Pieron CA. Journal of Cystic Fibrosis 1 (2002) S209-214.
Dentice RL, Elkins MR, Bye PTB. Journal of Physiotherapy 2012 Vol. 58.
Devadason SG, Walker SL, Le Souef PN. ATS Poster 2003.
Dimakou K, Triantafillidou C, Tsikritsaki A, Gousiou A, Dervas A, Toumbis M. ERS 2014, P244.
Durairaj L et al. Journal of Cystic Fibrosis 6 (2007) 31-34.
Durairaj L et al. Respiratory Research 2006.
Elhissi AM, Ahmed W, Taylor KM. J Nanosci Nanotechnol. 2012;(8):6693-9.
Elkins MR, Robinson M, Rose BR, et al. N Engl J Med. 2006;354(3):229-40.
Emeryk A et al. Postepy Dermatol Alergol. 2022;39(6):1027-34.
Fischer R et al. ERS Conference Munich, September 2-6. 2006.
Fischer R, Nährig S, Kerscher M, Huber RM. J Cystic Fibr. 2007;6 (suppl1):S41.
Fischer R et al. Drug Delivery to the Lungs, Volume 33, 2022
Geller DE, Pitlick WH, Nardella PA, Tracewell WG, Ramsey BW. Chest 122, 1, July 2002.
Govoni M et al. Pulm Pharmacol Ther. 2013 Apr;26(2):249-55.
Griese M et al. J Aerosol Med Pulm Drug Deliv. 2014;27(3):185-92.
Grzelewska-Ryzmowska I et al. Respiratory Medicine Vol. 97 (2003) (Supplement B), S21-26.
Hallstrand TS, Ochs HD, Zhu Q, Liles WC. Eur Respir J. 2004;24(3):367-70.
Hennig S et al. Journal of Cystic Fibrosis 13 (2014) 428–43.
Hickey A et al. Journal of Aerosol Medicine. Volume 19, Number 1, 2006.
Hodson ME, Gallagher CG, Govan JRW. Eur Respir J 2002: 20: 658-664.
Hubert D, et al. J Cyst Fibros. 2009 Sep;8(5):332-7.
Itazawa T, Adachi Y, Ito Y, et al. Allergol Int. 2013;62(1):131-135.
Jauernig J, Jahn D, Balcke A, Keller M. Drug Deliv Lungs. 2001;XII:179-182.lf.
Kastelik JA et al. 95th, 96th, and 97th International Conference, 2001, Poster C6.
Khan MY, Stirling MJ, Powles NT, Chrystyn H. ECFS Hambg 2011. Poster 109.
Konstan, M, Chou, W., Xu, Y., Trzaskoma, B., Sawicki, G. NACF Conference 2013, P668.
Langridge PJ, Sheehan RL, Denning DW. BMC Pulmonary Medicine (2016) 16:23.
Lenney W, Edenborough F, Kho P, Kovarik JM. J Cyst Fibros. 2011;10(1):9-14.
Lenoir G et al. Paediatr Drugs. 2007;9 Suppl 1:11-20.
McKenzie J, Cruz-Rivera M, Hoag J. 2001 Meeting of the American Thoracic Society, Poster D50.
McKenzie JE, Cruz-Rivera M. The Annals of Pharmacotherapy 2004 June, Volume 38.
Melani AS et al. Rassegna Di Patologia Dell'apparato Respiratorio. 2006;21:61-7.
Milani GKM. Rosario filho NG, Riedi CA, Figueiredo BC. Jornal de Pediatria- Vol. 80, No 2, 2004.
Monton C et al. Int J Chron Obstruct Pulmon Dis. 2019 Oct 17; 14:2365-2373.
Moore JE et al Posterpresentation North American Cystic Fibrosis Conference (NACF) 2020.
Moore JE et al. Respir Care. 2021 Sep;66(9):1446-1457.
Moss RB et al. Chest. 2004 Feb;125(2):509-21.
Moss RB. Chest, 120, 3, September, 2001, Supplement.
Murray TS, Towle D, Callan D, Lamprea C, Netter F. NACF Conference 2013, P330.
Naehrig S, Lang S, Schiffl H, Huber RM, Fischer R. Eur J Med Res. 2011 Feb 24;16(2):63-6.
Nguyen T, Banerjee PS. Poster aaps. 2003.
Nguyen T, Barron M, Miyawa J, Banerjee PS. Poster aaps. 2003.
O'Connell OJ et al. Respiratory Care. 2011;56(6):771-775.
O'Toole C et al. Eur J Pharm Sci. 2023 Aug 1;187:106474.
Pabary R, Alegro A, Alton E, et al. ECFC Conference 2015.
Poli G et al. Paediatr Drugs. 2007;9 Suppl 1:3-9.
Poli G, Acerbi D. Respiratory Medicine, Vol. 97 (2003) (Supplement B), S5-9.
Quinn D, Barnes CN, Yates W, et al. Pulm Pharmacol Ther. 2018;48:71-79.
Ratjen F, Munck A, Kho P, Angyalosi G; ELITE Study Group. Thorax. 2010 Apr;65(4):286-91.
Rudolph C, Müller RH, Rosenecker J. J Gene Med. 2002;4(1):1-10.
Sands D et al. T100 Study Group. J Cyst Fibros. 2014 Dec;13(6): 653-60.
Sands D, Sapiejka E, Mazurek H, Gaszczyk G. In: ECFC Conference 2013, P70.

San Miguel-Pagola M et al. Physiotherapy. 2019 Nov 11;107:243-251.
Sawicki GS et al. J Cyst Fibros. 2015 Nov;14(6):777-83.
Schuschnig U et al. https://www.researchgate.net/publication/342987954. July 2020.
Sommerer K, Pechtold O, Stegemann J, Paulukat J. Poster. 2006:1.
Standaert TA et al. Journal of Aerosol Medicine. Volume 13, Number 2, 2000.
Tazawa R, Hamano E, Arai T, et al. Am J Respir Crit Care Med. 2005;171(10):1142-9.
Tazawa R, Nakata K, Inque Y, Nukiwa T. Respirology (2006) 11, S61-64.
Terzano C, Cremonesi G. Eur Respir J 16 (Supple 31). 305s, 2000.
Towle D, Callan DA, Farrel PA, Egan ME, Murray TS. J Cyst Fibros. 2013;12(5):512-516.
Towle D, Callan DA, Lamprea C, Murray TS. J Hosp Infect. December 2015.
Twiss J et al. International Journal of Pharmaceutics 295 (2005) m 113-119.
Twiss J et al. Journal of Paediatrics and Child Health. 2022:jpc.15899.
Vaghi A et al. Pulmonary Pharmacology & Therapeutics 18 (2005) 151-153.
Van Velzen AJ et al. J Aerosol Med Pulm Drug Deliv. 2016 Jun;29(3):273-80.
Van Velzen AJ, Uges JWF, Arets HGM, et al. ECFC Conference 2015.
Vecellio L et al. Journal of Cystic Fibrosis. 2011;10(2):86-92.
Wang Z, Chen HT, Roa W, Finlay WH. J Pharm Pharm Sci. 2003;6(1):95-100.
Weigand AN, Cambridge L, Schuschnig U. Nacf. 2008.
Wenzel S et al. The Lancet, Vol 370, October 20, 2007.
Westerman EM et al. J Aerosol Med Pulm Drug Deliv. 2008 Sep;21(3):269-80.
Yonge C, Payne S, Legg J. ECFC Conference 2012, P203.

PARI LC SPRINT nebuliser

Albasarah YY, Somavarapu S, Stapleton P, Taylor KMJ Pharm Pharmacol. 2010;62(7):821-8.
Aubriot A, Lebecque P, Teresinha L, Liistro G, Reychler GNACF Conference 2016.
Berg EB, Picard RJ. Respir Care. 2009;54(12):1671-8.
Bitterle E, Müller D, Tiffin N, et al. Pediatr Pulmonol. 2007; (suppl 30):336.
Brendel E, Luithlen A, Bruendl K, et al. Am J Resp Care. 2010;181.
Brendel E, Luithlen A, Bruendl K, et al ECFC 2010 (Poster 163).
Buchmann NA. ISAM Poster 2015.
Bucholski A, Hug M, Keller M. Isam. 2007.
Buttini F, Rossi I, Di Cuia M, et al. Int J Pharm. 2016;502(1-2):242-248.
Chang KH et al. Pharmaceutics. 2020;12(8):721.
Chang KH et al. AAPS PharmSciTech. 2023 May 24;24(5):125.
Crater GD et al. Ther Adv Respir Dis. 2022;16:17534666221077561.
Devadason SG, Murdzoska J, Ditcham W, Roller CM. DDL Congress, December 2012
DeVincenzo J et al. J Infect Dis. 2022;225(12):2087-96.
Donohue JF et al. Pulm Pharmacol Ther. 2019 May 29:101808.
Donohue JF et al. BMC Pulm Med. 2020 May 11;20(1):134.
Donohue JF et al. Respir Med. 2023 Mar;208:107123.
Ferguson GT et al. Chronic Obstr Pulm Dis. 2019; 6(2).
Fischer R et al. ERS Conference Munich, September 2-6. 2006.
Fischer R et al. Posterpresentation European Respiratory Society (ERS) 2023.
Fischer R EMJ Respir. 2023 Vol. 11[1] Pages 69-73
Haworth CS et al. Lancet Respir Med. 2019 Jan 15. pii: S2213-2600(18)30427-2.
Keller M, Bucholski A, Hug M, Tillmanns S. ERS Conference Munich, September 2-6. 2006.
Keller M, Hug M, Bucholski A, Tillmanns S. Gpp. 2007.
Keller M, Schuschnig U, Hug M, Bucholski A. RDD Europe. 2007.
Koch M, Mentzel H, Ledermüller R. PA1251, Session 123.
Langridge PJ, Sheehan RL, Denning DW. BMC Pulmonary Medicine (2016) 16:23.
Lin J et al. J Thorac Dis 2017;9(2):372-385.
Mahler DA et al. Chronic Obstr Pulm Dis. 2019;6(4):321- 331.
Mansour MM, Smaldone GC. Respiratory Care. 2012.
Najlah M, Parveen I, Alhnan MA, et al. Int J Pharm. 2014;461(1-2): 234-241.
Nasr M, Najlah M, D'Emanuele A, Elhissi A. Int J Pharm. 2014;461 (1-2):242-250.
Perkins W, Li Z, Wenker A, Mullinger B. Pediatr Pulmonol. 2007; (suppl 30):356.
Ratjen F et al. Lancet Respir Med. 2019 Jun 6. pii: S2213-2600 (19)30187-0.
Quinn D, Barnes CN, Yates W, et al. Pulm Pharmacol Ther. 2018;48:71-79.
Schuschnig U et al. https://www.researchgate.net/publication/342987954. July 2020.
Schuschnig U et al. J Aerosol Med Pulm Drug Deliv. 2022 Jan;35(1):25-31.
Siler TM et al. Chronic Obstr Pulm Dis. 2020; 7(2): 99-106.
Stahl M et al. Poster NACFC - Indianapolis. USA; 2017.
Tiffin N, Zeman L. Poster 1494; ATS, New Orleans 2010.
Tillmanns S et al. Atemwegs- und Lungenkrankheiten. 2006;32(3):124-5.
Van Velzen AJ et al. J Aerosol Med Pulm Drug Deliv. 2016 Jun;29(3):273-80.
Vecellio L, Abdelrahim ME, Montharu J, Galle J, Diot P, Dubus J-C. 2011;10(2):86-92.
Walz-Jung H, Kamin W, Krämer I. Eur Respir J. 2013;42(Suppl 57):P2406.
Walz-Jung H, Kamin W, Krämer I. Eur Resp J 2014 Vol 44 Issue Suppl 58 Poster 3570. 2014.
Weigand AN, Cambridge L, Schuschnig U. NACF 2008.

PARI PEP System

Aubriot A et al. (2016), Poster Session Abstracts. Pediatr Pulmonol., 51: S194-S485.
Berlinski A, Hayden JP. Pediatr. Pulmonol., 45: 220-459.
Berlinski A. Respir Care. 2014 Feb;59(2):216-22.
Brochu A et al.. Journal of Cystic Fibrosis, Volume 14, Supplement 1, June 2015, Page S9.
Filipow N et al. Eur Respir J. 2023;62(3).
Hawes R, Worger C. Journal of Cystic Fibrosis. 2023;22.
Orlik T, Sands D. Dev Period Med. 2015 Jan-Mar;19(1):50-9.
Poncin W, Reychler G, Liistro M, Liistro G. Respir Care. 2020 Apr;65(4):492-499.
Raywood E et al. J Cyst Fibros. 2023;22(2):344-51.
Reychler G et al. Braz J Phys Ther. 2015 Nov-Dec;19(6):451-6.
Reychler G et al. Physiother Theory Pract. 2018 Feb 27:1-7.

PARI Filter Valve Set

Dhanak M et al. Cureus 2023;15(12):e50611.
Hautzel H et al. Abstract DGP Tagung 2022
Schuschnig U et al. Research Gate 2020
Hautzel H et al. Posterpräsentation DGP 2022

VORTEX

Bakuridze L, Neckermann S, Andrieu V, Dubus JC. Eur Resp J 2006; 28(suppl 50):PA4098
Berlinski A, Cooper B. Respir Care 2016; 61(7):913-919.
Buchmann NA, Kohlmann D, Steinführer K. Eur Resp J 2017;50 (suppl 61):PA3956.
Golshahi L, Zuberbuhler P, Finlay W. CHEST 2010;138(4):162A.
Goncalves TM, Alhanout K, Nicolay A, Dubus JC, de Santana DP, Andrieu V. J Aerosol Med Pulm Drug Deliv 2013;26(4):223-227.
Goncalves TM, Rizzo JA, Dubus JC, Nicolay A, de Santana DP, de Souza PHN, Figueiroa JN, Andrieu V. Lat Am J Pharm 2012; 31(6): 877-82.
Hagedoorn P, Bawary W, Frijlink HW, Grasmeijer F J. Allergy Clin Immun Pract 2020;8(3):1124-1125.e4.

Pourchez J, Leclerc L, Sarry G, Vergnon JM, Dubus JC. Rev Mal Respir 2017;34(1):29-35.
Rau JL, Coppolo DP, Nagel MW, Avvakoumova VI, Doyle CC, Wiersema KJ, Mitchell JP. Respir Care 2006;51(5):503-510.
Soderholm Labre A, Merk S, Kummer F, Behrenbruch K. Eur Resp J 2011;38(suppl 55):p4830:PA1503.
Voeurng V, Andrieu V, Bun H, Reynier JP, Dubus JC. Pediatr Allergy Immunol 2006;17(8):629-34
Winzen A, Steinfuehrer K, Schuschnig U, Seemann S. Respiratory Drug Delivery 2022:315-320.
Winzen A, Popp EM, Steinfuehrer K, Ledermueller R. Eur Resp J 2022:60(suppl 66):PA2007
Winzen A, Steinfuehrer K, Burmeister Y, Ledermueller R. Eur Resp J 2023:62(suppl 67):PA5368
Winzen A, Roßmann L, Burmeister Y, Riedel P, Steinfuehrer K. Drug Delivery to the Lungs 2023:34
Winzen A, Steinfuehrer K, Schlun M, Riedel P. Respiratory Drug Delivery 2024:370-374.
Winzen A, Roßmann L, Steinfuehrer K, Burmeister Y, Perera A, Ledermüller R. Eur Resp J 2024:64(suppl 68):PA2233
Zuberbuhler P, Wang Z, Finlay WH. CHEST 2002;122(4):P427.

Saline solutions

Robinson M et al. Thorax 1997; 52, 900–3
Elkins MR et al. Pediatr Pulmonol. 2006;(supplement 29):292.
Kellet et al; Respir Med. 2011,105(12):1831-1835
Pyne H. Nurs Times. 2011;107(30-31):21-22.
O'Connell OJ et al. Respir Care. 2011;56(6):771-775.
Dwyer T et al. J Cyst Fibr. 2013;12(Supplement 1):S19.
Subbarao, P. et al., Am J Respir Crit Care Med 188, 456–60 (2013).
Graf Z et al. Posterpräsentation GPP 2013; .
Nicolson, C. H. H. et al. Respiratory Medicine 106, 661–667 (2012)
Everard ML et al. Thorax. 2014;69(12):1105-1112.
Everard ML et al. Health Technol Assess. 2015;19(66):1-130.
Koch M et al. 2015; GPP A/B 7.
Mainz JG et al. J Cyst Fibros. 2016;15(6):e57-e66.
Ellemunter H et al., J Cyst Fibros. 2016 Jan;15(1):123-6.
Angoulvant F et al. JAMA Pediatr. 2017;171(8):e171333.
Carsin A et al. Respiration. 2017;94(3):251-257.
Stahl M. et al. Poster NACFC - Indianapolis. USA; 2017.
Kanjanapradap T et al., Pediatr Pulmonol 2018 Vol. 53 Issue 2 Pages 138-144
Schmailzl B et al. DGP Dresd 2018. V237.
Wittmann M et al. DGP Dresd 2018. P395.
Trimble AT et al. J Cyst Fibros 2018;17:650–6.
Stahl M et al. Am J Respir Crit Care Med. 2019;199(10):1238–48.
Bernek V et al. Posterpresentation DGP/GPP 2019.
Ratjen F, et al., Lancet Respir Med. 2019 Sep;7(9):802-809.
Donaldson SH et al. J Cyst Fibros Off J Eur Cyst Fibros Soc. November 2020;19(6):942–8.
Sapkota S et al. J Pak Med Assoc 2020:1–10.
Ollmann-Selinger M et al. Posterpresentation ERS 2020.
Bennett WD et al. ERJ Open Res 2020; 6: 00269-2020
Anuradha KWDA et al., Pediatr Pulmonol. 2021 Feb; 56(2):509-515. doi: 10.1002/ppul.25206. Epub 2020, Dec 23.
Galaz Souza N et al. Eur Respir J 2021; 57: 2001407.
González-Montaos A. R.-H. et al. 2022 Vol. 160 Issue 2023 Pages 23-26
Tiddens HAWM et al.. The Lancet Respiratory Medicine. 2022;10(7):669-78
Beigmohammadi, M.T., et al., Sci Prog, 2023. 106(4)
Chen, Y., et al., J Cyst Fibros, 2023. 22(5): p. 916-925.
T. J. Dwyer, M. R. Elkins, et al., Eur Respir J 2023 Vol. 62 Issue 1
Naveed H et al. Ann Med Surg (Lond). 2023 Sep 5;85(11):5484-5490.
Rudnyk V et al., Wiad Lek. 2023;76(6):1406-1412.

Ectoin

Graf R et al. Clin Dermatol 2008;26:326–33.
Eichel A et al Curr Med Res Opin. 2013;29(7):739-746.
Eichel A et al J Allergy. 2014; 1-12.
Sonnemann U et al J Allergy. 2014; 1-12.
Sonnemann U et al J Allergy. 2014; 1-10.
Werkhäuser N et al J Allergy. 2014; 1-13.
Unfried K et al J Allergy. 2014;2014:1-7.
Abdulkerimov Kh.T. et al Ross Otorinolaringol. 2016;2(81):127-133.
Unfried K et al Int J Chron Obstruct Pulmon Dis. 2016;11:2573.
Bownik A et al Arch Ind Hyg Toxicol. 2016;67(4).
Müller D et al. Eur Arch Otorhinolaryngol 2016;273:2591–7.
Tran B-H et al. BioMed Res Int 2019;2019:1–8.
Dao V-A et al. Eur Arch Otorhinolaryngol 2019;276:775–83.
Bilstein A et al. Brussino L (ed.). BioMed Res Int 2021;2021:1–16.

eFlow

Accurso F et al. Posterpresentation ERS conference 2010.
Adachi Y S et al. Allergology International. 2006;55:167
Adorni G et al. Pharmaceutics. 2019;11(8).
Assael BM Expert Rev Anti Infect Ther. 2011 Nov;9(11):967-73.
Ball R et al. Pediatr Pulmonol. 2006;41(suppl 29):330.
Baravalle-Einaudi M et al. Pulm Pharmacol Ther. 2017 Jun;44:57-60.
Barker AF et al. Lancet Respir Med. 2014 Sep;2(9):738-49.
Basu K et al. Ann Allergy Asthma Immunol. 2009; 103(5):436.
Baumann R et al. Eur J Pharm Sci. 2012 Apr 11;45(5):693-7.
Beck-Broichsitter M et al. Eur J Pharm Biopharm. 2014 Aug;87(3):524.
Beck-Broichsitter M et al. Int J Pharm. 2014 Jan 30;461(1-2):34-7.
Beck-Broichsitter M et al. J Pharm Sci. 2014 Aug;103(8):2585-9.
Beck-Broichsitter M Eur J Pharm Biopharm. 2017 Oct;119:11-16.
Beck-Broichsitter M J Pharm Sci. 2017 Aug;106(8):2168-2172.
Behr J et al. J Aerosol Med Pulm Drug Deliv. 2009 Jun;22(2):121-30.
Berndt R et al. Posterpresentation ERS conference 2012.
Bilton D et al. Posterpresentation NACF 2013.
Birring SS et al. Lancet Respir Med. 2017 Oct;5(10):806-815.
Bock DE et al. Eur Respir J. 2006; 28(suppl 50):485s.
Bos AC et al. PLoS One. 2015 Mar 3;10(3):e0118454.
Buchmann NA et al. Posterpresentation ISAM congress 2015.
Buchmann NA et al. Posterpresentation ISAM congress 2017.
Bucholski A et al. Posterpresentation German CF Conference DMT 2012 and ECFC 2012.
Bucholski A et al. Posterpresentation ISAM, Rotterdam, NL, June 2011.
Bucholski A et al. Posterpresentation NACF 2011.
Buttini F et al. Int J Pharm. 2016 Apr 11;502(1-2):242-8.
Chan JG et al. J Aerosol Med Pulm Drug Deliv. 2012 Oct;25(5): 297-305.
Coates AL et al. J Aerosol Med Pulm Drug Deliv. 2011 Jun;24(3): 157-63.
Coates AL et al. Pediatr Pulmonol. 2008; 43(s31):367.
Coates AL et al. Pediatr Pulmonol. 2011; 46:401-4087.
Dalla-Bona AC et al. Drug Dev Ind Pharm. 015;41(10):11117.
Denk O et al. Posterpresentation RDD Europe, Nice, France, May 2015.
Denk O et al. Posterpresentation RDD, Phoenix, USA, May 2012.
Donaldson SH Et al. Posterpresentation NACF 2013.
Donaldson SH et al. Posterpresentation NACF 2013.
Dupont LJ et al. Am J Respir Crit Care Med . 2010; 181:1836.
Elkins MR et al. Pediatric Pulmonology. 2006(supplement 29):292.
Elkins MR oral presentation ECFC Lisbon 2013.
Ellemunter H et. Al., Journal of Cystic Fibrosis. 2016 Jan;15(1):123–6.
Ferguson GT et al. Respir Med. 2017 Nov;132:251-260.
Fischer R et al Posterpresentation ÖGP 2020
Fischer R et al. J Cyst Fibr. 2007; 6(suppl 1):S41.
Fuchs C et al. Posterpresentation ERS congress 2017.
Fuchs C et al. Posterpresentation ISAM congress 2015.
Fuchs C et al. Posterpresentation ISAM, Rotterdam, NL, June 2011.
JAMP 2011;24(3):46.
Fuchs C et al. Posterpresentation NACF 2011.
Gallem T et al. ONdrugDelivery Publishing 2014, June 19th ;50,13-16.
Geller DE et al. Am J Respir Crit Care Med 2011; 183: 1510.
Geller DE et al. Pediatr Pulmonol. 2008; 43(31):315.

Gibson RL et al. Pediatr Pulmonol. 2006; 41(7):656.
Goss CH et al. Pediatric Pulmonology. 2009; 44(suppl 32):295.
Govoni M et al. Pulm Pharmacol Ther. 2013 Apr;26(2):249-55.
Grasemann H et al. Posterpresentation ATS conference 2008.
Griese M et al. Am J Respir Crit Care Med. 2013 Jul 1;188(1):83-9.
Griese M et al. JAMP 2014;27(3):185-192.
Griese M et al. Pediatr Pulmonol. 2009; 44(s32):300.
Guy EL et al. J Cyst Fibros. 2010; 9(4):292.
Hertel S et al. Eur J Pharm Biopharm. 2014 Jul;87(2):386-94.
Hubert D et al. J Cyst Fibr. 2007; 6(suppl 1):12.
Hubert D et al. Journal of Cystic Fibrosis. 2009; 5(5):332
Hütten MC et al. Ped Res 2015;78: 664-669.
Jud C et al. ISAM congress) JAMP 2013;26(2):A-54f.
Keller M et al. Exp Opin Drug Deliv 2011;8(1):1-17.
Keller M et al. ISAM, Rotterdam, NL, June 2011.
Keller M Thieme Drug Report 2010;4(10):12-15.
Kerem E et al. Pediatr Pulmonol. 2009; 44(32):303.
Kerwin E et al. Respir Med. 2017 Nov;132:238-250.
Khoo JK et al. J Aerosol Med Pulm Drug Deliv. Published online January 30, 2019.
Klemmer A et al. Pulm Pharmacol Ther. 2013 Sep 10.
Klemmer A et al. Pulm Pharmacol Ther. 2014 Jun;28(1):53-9.
Knoch M J Aerosol Med Pulm Drug Deliv. 2024 Jun;37(3):157-165.
Kollef MH et al. Chest. 2017 Jun;151(6):1239-1246.
Kramer MR et al. ERS conference. 2008:3670.
Leaker BR et al. Br J Clin Pharmacol. 2015 Mar;79(3):492-500.
Lee JH et al. J Liposome Res. 2013 Dec;23(4):336-42.
Lenney W et al. J Cyst Fibros. 2011; 10(1):9.
Lightwood D et al. J. Mol. Biol. 2013;425:577-593.
Linner R et al. ISAM congress) JAMP 2013;26(2):A-28.
Linner R et al. Neonatology. 2015;107(4):277-82.
Militz S et al. Journal of Cystic Fibrosis. 2008; 7(2):S67.
Minocchieri S et al. Pediatr Pulmonol. 2014 Apr;49(4):348-56.
Moeller W et al. DDL22, Edinburgh, United Kingdom, December 7-9, 2011. Proceedings:77-80.
Moeller W et al. ISAM, Rotterdam, NL, June 2011. JAMP 2011;24(3):37-38.
Montgomery AB et al. Antimicrob Agents Chemother. 2014 Jul;58(7):3714-9.
Montgomery AB et al. J Aerosol Med Pulm Drug Deliv. 2014 Dec;27(6):441-8.
Mundt C et al. Int Scholary Res Network, ISRN Pediatrics, vol 2012, article ID 721295.
Mundy L, Hiller JE Australian HTA Report 2015.
Naehrig S et al. Eur J Med Res. 2011 Feb 24;16(2):63-6.
O'Riordan TG et al. Posterpresentation NACF.
Oermann CM et al. Journal of Cystic Fibrosis. 2009; 8(suppl 2):28.
Parkins MD et al. Expert Rev Respir Med. 2010 Aug;4(4):435-44.
Perkins W et al. Pediatr Pulmonol. 2007(suppl 30):356.
Pham S et al. J Aerosol Med Pulm Drug Deliv. 2017 Nov 10.
Pitance PT et al. J Aerosol Med Pulm Drug Deliv. 2010 Dec;23(6):38.
Poncin A et al. DDL22, Edinburgh, United Kingdom, December 7-9, 2011. Proceedings:238-241.
Pritchard JN et al., Ther Deliv. 2018;9(2):121-136.
Retsch-Bogart GZ et al. Pediatr Pulmonol. 2008; 43(1):47.
Reychler G et al. J Cyst Fibr. 2007; 6(suppl 1):S67.
Rietschel E et al. Posterpresentation NACF conference 2010. 2010; 283:1.
Rottier BL et al. J Aerosol Med Pulm Drug Deliv. 2009 Sep;22(3):263-9.
Sands D et al. J Cyst Fibros. 2014 Dec;13(6):653-60.
Sands D et al. Posterpresentation ECFC, Lisbon 2013.
Santus P et al. Drug Des Devel Ther. 2017 Nov 15;11:3257-3271.
Scherer T et al. J Pharm Sci. 2011 Jan;100(1):98-109.
Schüepp KG et al. J Aerosol Med. 2005 Summer;18(2):225-35.
Schuschnig U et al. 2 Posterpresentation ISAM congress 2015.
Solé A et al. Am J Transplant. 2018 Feb;18(2):504-509.
Stanford, G. et al. Cochrane Database Syst Rev, 2023. 11(11): p. CD007639
Stephenson JJ EM.Internat J COPD 2020:15 1713–1727.
Thuilliez C et al. J Cyst Fibr. 2008; 7(suppl 2):67.
Tiddens H et al J Cys Fibros.14 (2015) 111-119.
Tiemersma S et al. J Aerosol Med Pulm Drug Deliv. 2013 Oct;26(5):280-6.
Tservistas M et al. Posterpresentation ECFC conference 2011.
Tservistas M et al. Inhalation Magazine 2011;5(5):8-13.
Tservistas M et al. Posterpresentation ECFC 2011.
Tservistas M et al. Posterpresentation ICAAC conference 2014.
Tullis E et al. J Cyst Fibros. 2014 May;13(3):296-30.
Van der Merwe SM et al. Archives of Disease in Childhood 2012 Vol. 97 Issue 5 Pages e15-e16.
Van Koningsbrruggen-Rietschel S et al. J Antimicrob Chemother. 2016 Mar;71(3):711-7.

PARI SINUS

Becker S et al. Posterpräsentation Jahrestagung d. dt. HNO-Gesellschaft 2022.
Daniels T et al. Standards of Care & Good Clinial Practice for the Physiotherapy Management of CF. 2017, 3rd edition: 27.
Dieninghoff D et al. Posterpräsentation Deutsche Mukoviszidose Tagung 2017.
Geppe N et al. Posterpräsentation ERS Conf. 2009:4029.
Geppe N et al. Posterpräsentation ERS Conf. 2008:3985.
Hanga D et al Jahrestagung dt. HNO-Ges. 2012.
Haynes F et al. J Cyst Fibros 2018 17: S67.
Hoegerle C et al. Posterpräsentation 63. österreichischer Kongress 2019.
Hosseini S et al. doi: 10.1016/j.ijpharm.2019.04.019. Epub 2019 Apr 8.
Katsumi N et al. ORL Tokyo. 2008 51(1):15-21.
Leclerc L et al. Pharmaceuticals 2023 17;16(2):135-150
Mainz J et al. J Cyst Fibros 2008 7 (Suppl 2): S27.
Mainz J et al. J Cyst Fibros 2009 8: 10–14.
Mainz J et al. J Cyst Fibros 2010 9 (Suppl 1): S23.
Mainz J et al. J Cyst Fibros 2011 10: S21.
Mainz J et al. AmJResCriCare 2011 184:1089-1090.
Mainz JG et al. J Cyst Fibros. 2009 8 (Suppl 2):S69.
Mainz JG et al. Drug Des Devel Ther. 2014 10;8:209-17.
Mainz JG et al. J Cyst Fibros. 2014 13 (4):461-70.
Martins DA et al. Nat Comm 2020 Vol 11 Issue1 Pages 1160.
Mentzel H et al. ctajournal.com/content/3/S2/P38.
Meßmer C et al. Posterpresentation 27th ERS-ISIAN, London, UK 2018.
Möller W et al. Posterpräsentation RDD 2007.
Moeller W et al. Rhinology 47 (2009): 405–12.
Möller W et al. Otolaryngol Neck Surg. 2010 (142):382-88.
Möller W et al. Expert Opin Drug Deliv. 2010 7(11):1239-1245.
Möller W et al. Respir Drug Deliv. 2010:111-21.
Moeller W et al. Posterpresentation DMT 2011.
Moeller W et al. Posterpresentation EAC 2011.
Moeller W et al. Curr Opin Otolaryngol Head Neck Surg 2011;19: 48-53.
Moeller W et al. J Aerosol Med Pulm Drug Deliv. 27, Nr. 4 (August 2014): 255–63.
Naruto R et al. ORL Tokyo. 2008 51 (1):11-14.
Schuschnig U et al. Posterpresentation ECFS Conference, Valencia, Spain, 2010.
Schwarz C et al. S3_Mukoviszidose_Modul_2_2017-08-01.pdf: 59-63.
Solé A et al Posterpresentation ECFS Conference 2023
Thieme S et al. European Radiology 22, Nr. 10 (Oktober 2012): 2110–16.
Weiss B et al. Laryngo-Rhino-Otologie 2021 6: 100.
Weiss B et al. Posterpresentation European Rhinology Society (ERS) 2021.
Wilson et al. J Cyst Fibros. 2014 13 :449-454.

General Terms and Conditions of PARI GmbH

Sale and delivery of the products offered in the respective case by PARI GmbH to customers who are not consumers within the meaning of § 13 of the German Civil Code (hereinafter referred to as Customer(s)) shall be based on the following general terms and conditions (hereinafter referred to as General Terms and Conditions), unless on the basis of an offer and its acceptance PARI GmbH and the Customer agree otherwise for the individual case (hereinafter: Individual Contract).

1. Scope of General Terms and Conditions and Conclusion of Individual Contracts
(1) The General Terms and Conditions of PARI GmbH shall exclusively apply to the sale and delivery of products by PARI GmbH to the Customer. Conflicting or deviating terms or conditions of the Customer are not accepted by PARI GmbH unless expressly consented to in writing by PARI GmbH. The General Terms and Conditions of PARI GmbH shall apply even if PARI GmbH effects delivery to the Customer without reserva-tion despite knowledge of differing, conflicting or deviating terms or conditions on the part of the latter.
(2) These General Terms and Conditions shall also apply to all future transactions with the Customer, insofar as their objective is the purchase and delivery of products.
(3) All agreements concluded between PARI GmbH and the Customer for the execution of an Individual Contract shall be effective only when set down in writing or in text form.
(4) All offers by PARI GmbH shall be non binding, unless the quotations by PARI GmbH expressly provide otherwise. PARI GmbH shall be entitled to accept offers by the Customer within two weeks of receipt by PARI GmbH.

2. Delivery Time
(1) Delivery dates indicated by PARI GmbH shall represent only indicatory declarations and shall therefore be deemed only approximately agreed (approximate periods), unless they are expressly marked by PARI GmbH as "binding delivery dates" or to this effect by similar language and agreed in accordance with Clause 1, para. (2) of these General Terms and Conditions as binding under the Individual Contract.
(2) If an approximate period is exceeded, the Customer may request PARI GmbH in writing to deliver within a reasonable period. PARI GmbH shall be in default only after expiry of the period thus set.
(3) If a product ordered by the Customer should not be available, not be available by a binding delivery date, or not be available within the period set pursuant to para. (2), because PARI GmbH is not supplied, not sup-plied with the agreed quantity, not supplied with the agreed quality, or supplied belatedly, by a manufacturer or supplier through no fault of PARI GmbH and despite the contractual obligation of said manufacturer or supplier, PARI GmbH shall be entitled to withdraw from the Individual Contract. PARI GmbH shall immedia-tely inform the Customer as soon as it is foreseeable that the product ordered by the Customer will not be available or will be available only with a delay. In case of withdrawal, PARI GmbH shall refund any payments already received from the Customer without delay.
(4) Compliance with an approximate term or a binding delivery date shall require timely fulfilment of all the contractual obligations assumed by the Customer, in particular performance of the payments agreed in the Individual Contract and provision of any agreed collaterals. In any case, PARI GmbH reserves the defence of non performance of the contract.
(5) In the case of binding delivery dates, PARI GmbH shall be liable for damage due to delay in perfor-mance only in case of delay in delivery not brought about by intention or gross negligence on its part for each completed week of delay by payment of a lumpsum compensation amounting to 3 % of the price of the product affected by the delay, but to no more than 15 % of this value in total.
(6) Further legal claims and rights of the Customer from a delay in delivery shall remain unaffected. Compensation for damage that is not damage caused by delay shall be subject to Clause 5 of the present General Terms and Conditions.

3. Shipping and Proviso of Change
(1) If shipping of the goods ordered is required, this shall be done from the head office of PARI GmbH at the expense and risk of the Customer. Unless otherwise agreed, PARI GmbH shall be free to choose the carrier and the means of transport. The risk shall pass to the Customer upon delivery to the carrier even if delivery free of transportation charges has been agreed.
(2) PARI GmbH shall be entitled to effect partial deliveries, unless the Customer discernibly has no interest in a partial delivery.
(3) If delivery is delayed by circumstances for which the Customer is responsible, then the risk shall pass to the Customer already at the time of readiness for shipment. The costs incurred by the delay (in particular storage costs) shall be borne by the Customer.
(4) If the delivery is delayed by force majeure, e.g. mobilisation, war, civil unrest or similar events, e.g. strike or lockout, approximate periods and delivery dates shall be extended or postponed, respectively, by the duration of the aforementioned obstacles to delivery.
(5) PARI GmbH shall not be obliged to take out insurance for the products against damage in transit or to have such insurance taken out, unless such an obligation has been assumed by PARI GmbH in the Individual Contract.
(6) Unless otherwise agreed in the Individual Contract, PARI GmbH reserves changes to the technology, colour or function of the products until delivery, provided the requirements defined in the Individual Contract are substantially fulfilled, and the changes are reasonable for the Customer.

4. Liability for Defects
(1) PARI GmbH shall be liable towards the Customer for defects in the products in accordance with the present Clause 4 of the General Terms and Conditions. PARI GmbH reserves the right to offer any (ultimate) buyer that buys the product from the Customer to conclude an independent warranty agreement with PARI GmbH and/or the respective manufacturer of the products (hereinafter: Certificate of Warranty). In this case, the Customer undertakes to
(a) take any actions necessary for issuance of such a Certificate of Warranty with the (ultimate) buyer (e.g. stamping of the Certificate of Warranty);
(b) inform the (ultimate) buyer in case of any notice of defect by the (ultimate) buyer pro actively about the provisions of this Certificate; and
(c) avail itself of any supplementary performance offered by PARI GmbH.
The Customer's claims for defects against PARI GmbH, including any right of recourse by the Customer against PARI GmbH under § 478 of the German Civil Code, shall remain unaffected by the provisions of the Certificate of Warranty, unless this Clause 4 stipulates otherwise.
(2) In the case of a mutual commercial transaction, the claims for defects are subject to the Customer's proper fulfilment of its inspection and notification obligations under § 377 of the German Commercial Code. This shall also apply to any rights of recourse of the Customer under § 478 of the German Civil Code, if the Customer should have sold a defective product as part of a sale of consumer goods to a consumer.
(3) Customer's claims for defects shall expire 12 months after delivery of the products to the Customer. Claims for damages in case of intent or gross negligence, or in case of injury to life, limb or health of the Customer based on an intentional or negligent breach of duty by PARI GmbH, shall be subject to the sta-tutory limitation periods. Where longer periods are mandatory under applicable law – e.g. pursuant to §§ 478, 479 of the German Civil Code –, these time limits shall apply.
(4) Should the product delivered have a defect that was already existent at the time of the transfer of risk to the Customer, PARI GmbH shall – subject to timely notice under paragraph (2) of this Clause 4 of the General Terms and Conditions – at its own discretion rectify said defect or provide a replacement product. PARI GmbH must always be given the chance to supplementary performance within a reasonable time, insofar as § 478 I of the German Civil Code does not provide for the contrary. PARI GmbH shall be entitled to deliver a replacement product in the form of a product of higher quality, unless this is unreasonable for the Customer.
(5) The Customer shall make the product complained about because of a defect or suspected deficiency available to PARI GmbH for the purpose of examination, if it has not disposed of said product yet. Each return of products shall be coordinated with PARI GmbH in the individual case. If the Customer detects or suspects any deficiencies of the goods, it may no longer dispose of them.
(6) If the Customer has resold the products, particularly in the course of a sale of consumer goods to a consumer, the Customer may demand compensation of any expenses that were necessary to enable sup-plementary performance (hereinafter: Expenses) only if and insofar as all of the following conditions are met:
(a) The claims of the (ultimate) buyer against the Customer are demonstrably justified and do not exceed what is legally necessary in the individual case;
(b) the Expenses, including travel and transportation costs, have not been increased by the product having subsequently been transported abroad, unless such further transport was stipulated in the Individual Contract;
(c) the Expenses, including travel and transportation costs, have not been increased by the Customer having failed to avail itself of the option offered by PARI GmbH pursuant to para. (1) (c) of this Clause and to address the coordination under para. (5) of this Clause;
(d) the Expenses have not been incurred or increased by the (ultimate) buyer not having required defect removal based on a Certificate of Warranty provided by PARI GmbH, said failure of the (ultimate) buyer being attributable to the Customer;
(e) the Expenses have not been increased by the Customer having resold the product despite a suspicion of a deficiency known to the Customer; and
(f) the Customer provides evidence of the origin and the amounts of the respective Expenses.
PARI GmbH shall provide compensation for such Expenses on the part of the Customer up to a maximum of 10 % of the net purchase price of the product affected by the defect or € 15, whichever is higher in the individual case.
Further claims by the Customer based on § 478 of the German Civil Code shall be satisfied by PARI GmbH by granting the Customer an equivalent compensation within the meaning of § 478 IV 1 of the German Civil Code by provision of defect removal immediately in relation to the (ultimate) buyer under a Certificate of Warranty with a warranty period of at least twelve months from delivery to the (ultimate) buyer.
(7) No claims for defects on the part of the Customer shall be deemed justified in case of only minor devia-tion of a product characteristic from the quality agreed in the Individual Contract; of only minor impairment of the usability of the products; of natural wear and tear; and of damage arising after the transfer of risk due to faulty or negligent treatment, excessive stress, or as a consequence of particular external influences which are not expected under the Individual Contract. If the Customer or any third party should improperly perform repairs or modifications, for these and the resulting consequences any claims for defects shall likewise be excluded.
(8) Claims for damages by the Customer in the context of liability for defects shall be subject to Clause 5 of these General Terms and Conditions.
(9) Replacement in the context of liability for defects or based on a Certificate of Warranty shall not give rise to any new warranty or liability periods.

5. Liability of PARI GmbH
(1) Claims by the Customer for compensation and reimbursement of expenses (hereinafter: Claims for Damages), irrespective of the legal base, including infringement of contractual duties and tort, are excluded. This shall not apply in case of provision of a warranty or assumption of a procurement risk. This shall not apply either insofar as liability is mandatory, e.g. under the German Product Liability Act, in cases of intent or gross negligence or of injury of life, limb, or health of the Customer, as well as of breach of essential con-tractual obligations. However, the Claim for Damages in case of breach of essential contractual obligations shall be limited to foreseeable damage typical for the contract insofar as there is no gross negligence and no liability for injury to life, limb, or health of the Customer.
(2) The provisions of the preceding paragraph shall apply to all Claims for Damages, regardless of the legal base, in particular such as are due to defects, to breach of duties arising from the obligation or to tort. They shall also apply to claims for reimbursement of futile expenses.
(3) The Customer's right of rescission of the Individual Contract shall remain unaffected. This Clause 5 shall entail no change in the onus of proof to the Customer's detriment.

6. Terms of Payment
(1) Unless stipulated otherwise in the Individual Contract, the prices of PARI GmbH according to Clause 3 of these General Terms and Conditions shall apply "ex works", excluding shipping and excluding packaging costs; these are to be invoiced separately.
(2) The statutory VAT shall not be included in the prices of PARI GmbH; it will be presented separately in the invoice as applicable by law on the date thereof.
(3) Deduction of discount shall require a special stipulation in the Individual Contract.
(4) Unless agreed otherwise in the Individual Contract, the deliveries by PARI GmbH shall be effected only against prepayment, cash on delivery or provision of any other reasonable collateral.
(5) If and insofar as the Customer does not pay in accordance with para. (4) of this Clause 6 by prepayment, cash on delivery or collateral, the Customer shall pay immediately upon receipt of the invoice, unless a different term of payment has been agreed in the Individual Contract. The invoice will be issued simultaneously with the delivery.
(6) If the Customer is in arrears with respect to a claim or partial claim, PARI GmbH shall be entitled to effect further deliveries only against prepayment; to demand immediate payment for all outstanding invoices; and to effect further deliveries only subject to provision of a reasonable collateral.
(7) Withholding of payments or offsetting with any counterclaims of the Customer is excluded, with the exception of uncontested or non appealable claims. In addition, the Customer shall be entitled to exercise a right of retention only insofar as its counter claim is based on the same Individual Contract.
(8) All claims of PARI GmbH against the Customer, regardless of the underlying legal relationship, shall become due for payment immediately if and when any circumstances arise that entitle PARI GmbH to rescind an Individual Contract pursuant to statutory or contractual provisions.
(9) Payments shall be made, subject to the provisions in para. (3) and (7) of this Clause 6, without deduction by transfer to the bank account indicated by PARI GmbH, unless the Contracting Parties stipulate payment by the SEPA Business to Business Direct Debit Scheme in the Individual Contract. Any discount and bank charges shall be at the Customer's expense. The Contracting Parties agree that during the period of an agreed SEPA Business to Business Direct Debit procedure the term for advance information (notice) about a pending debit shall be shortened to five (5) days. The debit is to be notified by indication on the respective invoice.
(10) Until the end of the calendar year 2026, an invoice can also be sent as another invoice (invoice in paper form or in an electronic format that does not meet the requirements of § 14 (1) sentence 6 German Value Added Tax Act).

7. Retention of Title
(1) PARI GmbH shall retain title to the products delivered until full payment of all claims from the Individual Contract. This shall also apply to all future deliveries, even if PARI GmbH should not always expressly refer thereto. PARI GmbH shall be entitled to take back the product if the Customer breaches the contract.
(2) The Customer shall handle the products with care, as long as ownership has not been transferred. In particular, the Customer shall take out sufficient insurance at replacement value for them at its own expense against theft, fire and water damage. As long as ownership has not been transferred, the Customer shall notify PARI GmbH immediately in writing if the delivered goods are seized or exposed to other interference by third parties. If the third party is unable to reimburse PARI GmbH for the judicial and extrajudicial costs of an action pursuant to § 771 of the German Code of Civil Procedure, the Customer shall be liable for the loss incurred by PARI GmbH.
(3) The Customer shall be entitled to resell the retained goods in the ordinary course of business. Even hereby, the Customer assigns its claims against the (ultimate) buyer from the resale of the retained goods to PARI GmbH to the amount of the final invoice agreed with the latter (including VAT). The Customer shall remain entitled to collect the receivable even after the assignment. The entitlement of PARI GmbH to collect the receivable by itself shall remain unaffected thereby. However, PARI GmbH will not collect the claim as long as the Customer meets its payment obligations and is not in arrears, and in particular as long as no application for opening of insolvency proceedings has been filed and payments are not suspended.
(4) PARI GmbH undertakes to release the collaterals in its possession upon the Customer's request if their value exceeds the collateralised claims by more than 20%.

8. Change of Contracting Party
PARI GmbH is entitled to assign individual contracts to a third party, in particular to pharmaceutical wholesalers, unless opposed by legitimate interests of the Customer.

9. Vigilance
Distributors of PARI medical devices are obliged to meet the requirements of Regulation (EU) 2017/745 on medical devices, in particular Article 14 (General obligations of distributors).
Distributors that have received complaints or reports from healthcare professionals, patients or users about suspected incidents related to a PARI device they have made available, shall immediately forward this infor-mation to PARI. They shall keep a register of complaints, of non-conforming devices and of recalls and with-drawals, and keep PARI informed of such monitoring and provide PARI with any information upon request.

10. Applicable Law, Place of Performance and Legal Venue
If any provision of the present General Terms and Conditions or of the Individual Contract should be invalid or unenforceable, the remaining provisions thereof shall remain valid.
(2)The contractual relationship between PARI GmbH and the Customer shall be subject exclusively to the law of the Federal Republic of Germany, excluding its private international law and excluding the UN Sales Convention.
(3) The place of performance shall be the head office of PARI GmbH.
(4) As the exclusive legal venue, District Court Munich I is agreed.

Date: 2024-11

PARI GmbH Spezialisten für effektive Inhalation, Moosstraße 3, D-82319 Starnberg, Tel.: +49 (0)8151 279 0, Fax +49 (0)8151 279 101, E-Mail: info@pari.de, www.pari.com

PARI Service Center

+49 (0) 8151 279 220

We're here to help!

PARI's Export Service Coordinators in Starnberg, Germany, offer an expert service and are dedicated to assisting you personally with any questions regarding:

- Use and handling of PARI inhalation devices
- Cleaning and servicing
- Accessories and spare parts
- Product availability and lead-times
- Order processing and logistics

If you need information about a repair or service for a PARI device, please visit **www.pari.com/partners** to find a distributor and/or service partner in your country.

We look forward to hearing from you.
Simply give us a call or send an email to **export@pari.de** for a prompt response.

PARI GmbH
Moosstraße 3
82319 Starnberg
GERMANY
e-mail: export@pari.de
phone: +49 (0) 8151 279 220
fax: +49 (0) 8151 279 6220
www.pari.com

041D0282-K-2025-07